DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
O'Brien C, Godofsky E, Roriguez-Torres M. et al.
Randomized trial of valopicitabine (NM283) alone or with PEG-interferon vs. retreatment with PEG-interferon plus ribavirin (PEGIFN/RBV) in hepatitis C patients with previous non-response to PEGIFN.RBV: first interim results
Hepatology 2005; 42: 232A-
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.